Atrion Stock Forecast, Price & News

Atrion (NASDAQ:ATRI) Frequently Asked Questions

How has Atrion's stock price been impacted by COVID-19?

Atrion's stock was trading at $667.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRI stock has increased by 10.2% and is now trading at $735.20.
View which stocks have been most impacted by COVID-19.

When is Atrion's next earnings date?

Atrion is scheduled to release its next quarterly earnings announcement on Friday, February 25th 2022.
View our earnings forecast for Atrion.

How were Atrion's earnings last quarter?

Atrion Co. (NASDAQ:ATRI) announced its quarterly earnings data on Monday, November, 8th. The medical instruments supplier reported $4.58 earnings per share for the quarter. The medical instruments supplier had revenue of $42.86 million for the quarter. Atrion had a trailing twelve-month return on equity of 13.39% and a net margin of 20.58%.
View Atrion's earnings history.

How often does Atrion pay dividends? What is the dividend yield for Atrion?

Atrion declared a quarterly dividend on Friday, November 12th. Stockholders of record on Wednesday, December 1st will be paid a dividend of $1.95 per share on Wednesday, December 15th. This represents a $7.80 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date is Tuesday, November 30th.
View Atrion's dividend history.

Is Atrion a good dividend stock?

Atrion pays an annual dividend of $7.80 per share and currently has a dividend yield of 1.02%. Atrion has been increasing its dividend for 19 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Atrion is 44.07%. This payout ratio is at a healthy, sustainable level, below 75%.
View Atrion's dividend history.

Who are Atrion's key executives?

Atrion's management team includes the following people:

• David A. Battat, President & Chief Executive Officer
• Jeffery Strickland, Chief Financial Officer, Secretary, Treasurer & VP

What is David A. Batta's approval rating as Atrion's CEO?

1 employees have rated Atrion CEO David A. Batta on Glassdoor.com. David A. Batta has an approval rating of 100% among Atrion's employees. This puts David A. Batta in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Atrion's key competitors?

Some companies that are related to Atrion include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Neogen (NEOG), Merit Medical Systems (MMSI), Haemonetics (HAE), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR), Anika Therapeutics (ANIK) and Antares Pharma (ATRS).
View all of ATRI's competitors.

What other stocks do shareholders of Atrion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atrion investors own include International Paper (IP), AT&T (T), WestRock (WRK), AbbVie (ABBV), Caterpillar (CAT), Eastman Chemical (EMN), Gilead Sciences (GILD), Altria Group (MO), Pfizer (PFE) and Philip Morris International (PM).

What is Atrion's stock symbol?

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

Who are Atrion's major shareholders?

Atrion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (11.03%), Neuberger Berman Group LLC (10.97%), BlackRock Inc. (6.23%), Dimensional Fund Advisors LP (2.93%), Renaissance Technologies LLC (2.47%) and Boston Trust Walden Corp (1.78%). Company insiders that own Atrion stock include Emile A Battat and John P Stupp Jr.
View institutional ownership trends for Atrion.

Which major investors are selling Atrion stock?

ATRI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Kayne Anderson Rudnick Investment Management LLC, Renaissance Technologies LLC, Morgan Stanley, Thrivent Financial for Lutherans, Dimensional Fund Advisors LP, New York State Common Retirement Fund, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Atrion or view top insider-selling stocks.

Which major investors are buying Atrion stock?

ATRI stock was bought by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Boston Trust Walden Corp, Citadel Advisors LLC, Aviva PLC, Moors & Cabot Inc., Millennium Management LLC, Victory Capital Management Inc., and SG Americas Securities LLC.
View insider buying and selling activity for Atrion or or view top insider-buying stocks.

How do I buy shares of Atrion?

Shares of ATRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atrion's stock price today?

One share of ATRI stock can currently be purchased for approximately $735.20.

How much money does Atrion make?

Atrion has a market capitalization of $1.32 billion and generates $147.59 million in revenue each year. The medical instruments supplier earns $32.12 million in net income (profit) each year or $17.70 on an earnings per share basis.

How many employees does Atrion have?

Atrion employs 636 workers across the globe.

What is Atrion's official website?

The official website for Atrion is www.atrioncorp.com.

Where are Atrion's headquarters?

Atrion is headquartered at ONE ALLENTOWN PARKWAY, ALLEN TX, 75002.

How can I contact Atrion?

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The medical instruments supplier can be reached via phone at (972) 390-9800, via email at [email protected], or via fax at 972-396-7581.